GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data from a study with GlaxoSmithKline (NYSE: GSK) on EndoBarrier® and its potential mechanism of action were presented at Digestive Disease Week 2014 (DDW) during an oral presentation titled, “Duodenal-jejunal Bypass Liner Increases Fasting and Postprandial Serum Levels of Bile Acids in Patients with Severe Obesity.”
Help employers find you! Check out all the jobs and post your resume.
